Jiangsu Vcare’s Second-Generation Selective JAK1 Inhibitor VC005 Completes Phase II Enrollment for Moderate-to-Severe Atopic Dermatitis
Published Time:
2024-03-20 17:33
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of moderate-to-severe atopic dermatitis (AD). Preliminary blinded analysis from the clinical trial demonstrated promising efficacy and safety profiles for VC005.
About VC005
VC005 is a novel, highly potent, and selective JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug suppresses immune cell-mediated cytotoxicity and immune responses, while exhibiting minimal inhibitory activity against JAK2 and TYK2 (based on preclinical data). This selectivity is expected to mitigate safety concerns associated with excessive inhibition of non-target JAK isoforms, such as JAK2.
The drug is under development in two formulations: ① Oral tablets: Phase II trials for ankylosing spondylitis (AS)and moderate-to-severe AD are ongoing. Enrollment for the AS trial was completed by the end of 2023. Additional clinical indications, including IBD and RA, have been approved. Early Phase I studies demonstrated favorable pharmacokinetics, safety, and tolerability. ② Topical gel: Phase I trials for mild-to-moderate AD are nearing completion.
About JAK1
The JAK/STAT signaling pathway plays a critical role in the pathogenesis of inflammatory diseases such as AD. Current oral JAK inhibitors lack sufficient selectivity, simultaneously inhibiting JAK1, JAK2, which has been linked to severe adverse events (e.g., anemia, infections, dyslipidemia, malignancies) and prompted the U.S. FDA to issue black box warnings. Since the first half of 2021, the FDA has repeatedly delayed reviews of pan-JAK inhibitors, raising concerns in the biopharmaceutical industry. Consequently, the development of highly selective JAK1 inhibitors has become imperative. To date, no selective JAK1 inhibitors for AD have been approved in China, underscoring the urgent unmet clinical need.
VC005 was designed with a differentiated approach, addressing these challenges during its discovery and development phases. Preclinical studies showed that VC005 achieves lower effective doses, higher tolerated doses, and reduced side effects compared to other JAK1-targeted drugs. Early human trials further confirmed its favorable metabolic profile and safety, positioning VC005 as a potential global leader in the treatment of autoimmune and inflammatory diseases.
About AD
AD is a chronic, recurrent, inflammatory skin disorder characterized by dry skin, intense pruritus, and eczematous lesions. The disease severely impairs patients’ quality of life. Globally, AD affects approximately 230 million individuals, with over 70 million cases in China (adult prevalence: 2%-8%). Among these, 33% are moderate-to-severe cases, and prevalence continues to rise.
Current treatments rely on topical and systemic therapies, but traditional options (e.g., glucocorticoids) are limited by adverse effects and suboptimal efficacy, leaving many patients without stable disease control. In contrast, oral JAK1 inhibitors, as non-glucocorticoid immunosuppressants, offer a targeted approach with improved safety and prolonged therapeutic responses, providing a superior alternative for moderate-to-severe AD patients.
Next Page
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn